| P2093 | author name string | Yu-Hsuan Wu | |
| | Yu-San Chang | |
| | Chun-Yang Lai | |
| P2860 | cites work | Antipsychotic polypharmacy among patients admitted to a geriatric psychiatry unit. | Q50786649 |
| | Adjunctive benzodiazepine treatment of hospitalized schizophrenia patients in Asia from 2001 to 2008. | Q51606438 |
| | Effectiveness of antipsychotic drugs in patients with chronic schizophrenia | Q28273164 |
| | Antipsychotic treatments for the elderly: efficacy and safety of aripiprazole | Q33755676 |
| | National trends in psychotropic medication polypharmacy in office-based psychiatry | Q34090959 |
| | Impact of FDA black box advisory on antipsychotic medication use | Q34092198 |
| | Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. | Q34573456 |
| | Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia | Q35826319 |
| | Clinical experience with aripiprazole treatment in ten elderly patients with schizophrenia or schizoaffective disorder: retrospective case studies | Q35936263 |
| | The quality of antipsychotic drug prescribing in nursing homes | Q36163125 |
| | Combination antipsychotic therapy in psychiatric outpatient clinics in Taiwan | Q36564431 |
| | Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003. | Q36767032 |
| | Does the addition of a second antipsychotic drug improve clozapine treatment? | Q37147547 |
| | Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial | Q37271450 |
| | Persistent antipsychotic polypharmacy and excessive dosing in the community psychiatric treatment setting: a review of medication profiles in 435 Canadian outpatients. | Q37723434 |
| | Antipsychotics in dementia: prevalence and quality of antipsychotic drug prescribing in UK mental health services | Q38025938 |
| | Economic reforms and the acute inpatient care of patients with schizophrenia: the Chinese experience | Q39452430 |
| | Olanzapine vs. haloperidol in the treatment of elderly chronic schizophrenia patients | Q42688943 |
| | The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia. | Q44453886 |
| | Common use of antipsychotic polypharmacy in older Asian patients with schizophrenia (2001-2009). | Q45208844 |
| | Second-generation antipsychotic drug use in hospital inpatients with dementia: the impact of a safety warning on rates of prescribing. | Q46100895 |
| | Aripiprazole for the treatment of psychosis in patients with Alzheimer's disease: a randomized, placebo-controlled study | Q46701458 |
| | Psychotropic drug prescribing to chronic schizophrenics in a Hong Kong hospital | Q47330727 |
| | Use of first- and second-generation antipsychotic medications in older patients with schizophrenia in Asia (2001-2009). | Q47390596 |
| | Trends in antipsychotic use in dementia 1999-2007. | Q48915937 |
| P433 | issue | 1 | |
| P921 | main subject | schizophrenia | Q41112 |
| P304 | page(s) | 7-13 | |
| P577 | publication date | 2014-12-17 | |
| P1433 | published in | Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society | Q27020360 |
| P1476 | title | Antipsychotic polypharmacy among elderly patients with schizophrenia and dementia during hospitalization at a Taiwanese psychiatric hospital | |
| P478 | volume | 15 | |